These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 33141149)

  • 21. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
    Yurgin N; Secnik K; Lage MJ
    Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.
    Bizino MB; Jazet IM; van Eyk HJ; Rensen PCN; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Paiman EHM; Smit JW; Lamb HJ
    Acta Diabetol; 2021 Apr; 58(4):485-493. PubMed ID: 33399989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral antidiabetic therapy versus early insulinization on glycemic control in newly diagnosed type 2 diabetes patients: a retrospective matched cohort study.
    Lee YM; Lin PR; Sia HK
    Sci Rep; 2024 Jul; 14(1):15491. PubMed ID: 38969701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States.
    Fernandes G; Sawhney B; Hannachi H; Liu J; Wang T; Fu AZ; Iglay K; McNeill A; Rajpathak S
    Curr Med Res Opin; 2020 May; 36(5):741-748. PubMed ID: 31990206
    [No Abstract]   [Full Text] [Related]  

  • 27. Unmasking Fracture Risk in Type 2 Diabetes: The Association of Longitudinal Glycemic Hemoglobin Level and Medications.
    Wang B; Wang Z; Poundarik AA; Zaki MJ; Bockman RS; Glicksberg BS; Nadkarni GN; Vashishth D
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1390-e1401. PubMed ID: 34888676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Search for clinical predictors of good glycemic control in patients starting or intensifying oral hypoglycemic pharmacological therapy: A multicenter prospective cohort study.
    Ren Q; Ji LN; Lu JM; Li YF; Li QM; Lin SS; Lv XF; Wang L; Xu Y; Guo XH; Guo QY; Ma L; Du J; Chen YL; Zhao CL; Zhang QL; She QM; Jiao XM; Lu MH; Sun XM; Gao Y; Zhang J
    J Diabetes Complications; 2020 Feb; 34(2):107464. PubMed ID: 31771933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period.
    Mansour AA; Alibrahim NTY; Alidrisi HA; Alhamza AH; Almomin AM; Zaboon IA; Kadhim MB; Hussein RN; Nwayyir HA; Mohammed AG; Al-Waeli DKJ; Hussein IH;
    Diabetes Metab Syndr; 2020; 14(3):265-272. PubMed ID: 32272433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies.
    Hidayat K; Fang QL; Shi BM; Qin LQ
    Osteoporos Int; 2021 Sep; 32(9):1693-1704. PubMed ID: 33860816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).
    Gao L; Zhang P; Weng J; Lu J; Guo X; Jia W; Yang W; Zou D; Zhou Z; Pan C; Gao Y; Li X; Zhu D; Wu Y; Garg SK; Ji L
    J Diabetes; 2020 Sep; 12(9):668-676. PubMed ID: 32329194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
    Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
    Trials; 2020 May; 21(1):379. PubMed ID: 32370806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.
    Siegmund T; Pfohl M; Forst T; Pscherer S; Bramlage P; Foersch J; Borck A; Seufert J
    Diabetes Metab Syndr; 2017; 11(1):51-57. PubMed ID: 27578616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Associated with Diabetes Control in Predominately African American and Hispanic Population with Newly Diagnosed Type 2 Diabetes.
    Morkos M; Tahsin B; Fogelfeld L
    J Racial Ethn Health Disparities; 2021 Apr; 8(2):332-338. PubMed ID: 32557276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data.
    Cesta CE; Hernández-Díaz S; Huybrechts KF; Bateman BT; Vine S; Seely EW; Patorno E
    Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1350-1359. PubMed ID: 37461243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study.
    Patel S; Abreu M; Tumyan A; Adams-Huet B; Li X; Lingvay I
    BMJ Open Diabetes Res Care; 2019; 7(1):e000761. PubMed ID: 31803482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.
    Zintzaras E; Miligkos M; Ziakas P; Balk EM; Mademtzoglou D; Doxani C; Mprotsis T; Gowri R; Xanthopoulou P; Mpoulimari I; Kokkali C; Dimoulou G; Rodopolou P; Stefanidis I; Kent DM; Hadjigeorgiou GM
    Clin Ther; 2014 Oct; 36(10):1443-53.e9. PubMed ID: 25109773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between glycemic control and hip fracture.
    Puar TH; Khoo JJ; Cho LW; Xu Y; Chen YT; Chuo AM; Poh CB; Ng JM
    J Am Geriatr Soc; 2012 Aug; 60(8):1493-7. PubMed ID: 22862735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study.
    Bruderer SG; Bodmer M; Jick SS; Meier CR
    Ann Rheum Dis; 2015 Sep; 74(9):1651-8. PubMed ID: 24728333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.